Journal Mobile Options
Table of Contents
Vol. 7, No. 1-3, 2010
Issue release date: April 2010
Neurodegenerative Dis 2010;7:116–121

The Vascular Hypothesis of Alzheimer’s Disease: Bench to Bedside and Beyond

de la Torre J.C.
Banner Sun Health Research Institute, Sun City, Ariz., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The vascular hypothesis of Alzheimer’s disease (AD) which we first proposed in 1993, has become a useful concept in identifying vascular risk factors for AD or vascular dementia that can be modified through appropriate treatment to prevent, reduce or delay the onset of cognitive impairment and dementia onset. Among the more than two dozen vascular risk factors already identified for AD, are cardiovascular disease and carotid artery atherosclerosis, which may exert their pathology by chronically lowering cerebral hypoperfusion during aging. We propose and plan to initiate a clinical study to screen middle-aged, cognitively intact individuals, with carotid artery ultrasound and echocardiography to identify potentially progressive pathology in the heart and carotid artery that is considered modifiable with optimal medical treatment. This clinical strategy, if found effective in preventing pathologic conditions suspected of contributing to severe cognitive impairment, could significantly reduce AD prevalence if applied on a wide scale and help promote healthier mental and physical aging while providing a compelling economic benefit to society.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Alzheimer’s Association: 2009 Alzheimer’s disease facts and figures. Alzheimers Dement 2009;5:234–270.
  2. de la Torre JC, Mussivand T: Can disturbed brain microcirculation cause Alzheimer’s disease? Neurol Res 1993;15:146–153.
  3. Caselli RJ, Chen K, Lee W, Alexander GE, Reiman EM: Correlating cerebral hypometabolism with future memory decline in subsequent converters to amnestic pre-mild cognitive impairment. Arch Neurol 2008;65:1231–1236.
  4. Roher AE, Esh C, Kokjohn TA, Kalbak W, Luhers DC, Seward JD, Sue LI, Beach TG: Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer’s disease. Arterioscler Thromb Vasc Biol 2003;23:2055–2062.
  5. Milionis HJ, Florentin M, Giannopoulos S: Metabolic syndrome and Alzheimer’s disease: a link to a vascular hypothesis? CNS Spectr 2008;13:606–613.
  6. Helzner E, Luchsinger J, Scarmeas N, Cosentino S, Brickman A, Glymour M, Stern Y: Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 2009;66:343–348.
  7. Aguero-Torres H, Kivipelto M, von Strauss E: Rethinking the dementia diagnoses in a population-based study: what is Alzheimer’s disease and what is vascular dementia? A study from the Kungsholmen project. Dement Geriatr Cogn Disord 2006;22:244–249.
  8. Breteler MM: Vascular risk factors for Alzheimer’s disease: an epidemiological study. Neurobiol Aging 2000;21:153–160.
  9. Dede DS, Yavuz B, Yavuz BB, Cankurtaran M, Halil M, Ulger Z, Cankurtaran ES, Aytemir K, Kabakci G, Ariogul S: Assessment of endothelial function in Alzheimer’s disease: is Alzheimer’s disease a vascular disease? J Am Geriatr Soc 2007;55:1613–1617.
  10. Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, Pandya Y, Esh C, Connor DJ, Sabbagh M, Walker DG, Roher AE: Circle of Willis atherosclerosis: association with Alzheimer’s disease, neuritic plaques and neurofibrillary tangles. Acta Neuropathol 2007;113:13–21.
  11. Ruitenberg A, den Heiker T, Bakker SL: Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam study. Ann Neurol 2005;57:789–794.
  12. Lindsay J, Laurin D, Verreault R, et al: Risk factors for Alzheimer’s disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002;156:445–453.
  13. de la Torre JC: How do heart disease and stroke become risk factors for Alzheimer’s disease? Neurol Res 2006;28:637–644.
  14. de la Torre JC, Cada A, Nelson N, Davis G, Sutherland RJ, Gonzalez-Lima F: Reduced cytochrome oxidase and memory dysfunction after chronic brain ischemia in aged rats. Neurosci Lett 1997;223:165–168.
  15. de la Torre JC: Impaired brain microcirculation may trigger Alzheimer’s disease. Neurosci Behav Rev 1994;18:397–401.
  16. Hofman A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F: Atherosclerosis, apolipoprotein E and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet 1997;349:151–154.
  17. Casserly I, Topol E: Convergence of atherosclerosis and Alzheimer’s disease: inflammation, cholesterol, and misfolded proteins. Lancet 2004;363:1139–1146.
  18. van Oijen M, de Jong FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM: Atherosclerosis and risk for dementia. Ann Neurol 2007;61:403–410.
  19. de la Torre JC: Is Alzheimer’s a neurodegenerative or a vascular disorder? Data, dogma and dialectics. Lancet Neurol 2004;3:184–190.
  20. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K: Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005;64:277–281.
  21. Kilander L, Andren B, Nyman H, Lind L, Boberg M, Lithell H: Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men. Stroke 1998;29:1816–1820.
  22. Zuccalà G, Cattel C, Manes-Gravina E, Di Niro MG, Cocchi A, Bernabei R: Left ventricular dysfunction: a clue to cognitive impairment in older patients with heart failure. J Neurol Neurosurg Psychiatry 1997;3:509–512.

    External Resources

  23. de la Torre JC: Alzheimer’s disease prevalence can be lowered with non-invasive testing. J Alzheimers Dis 2008;14:353–359.
  24. de la Torre JC: Carotid artery ultrasound and echocardiography (CAUSE) testing to lower the prevalence of Alzheimer’s disease. J Stroke Cerebrovasc Dis 2009;18:319–328.
  25. de la Torre JC, Fortin T, Park G, Butler K, Kozlowski P, Pappas B, de Socarraz H, Saunders J, Richard M: Chronic cerebrovascular insufficiency induces dementia-like deficits in aged rats. Brain Res 1992;582:186–195.
  26. de la Torre JC, Fortin T, Park Saunders J, Kozlowski P, Butler K, de Socarraz H, Pappas B, Richard M: Aged but not young rats develop metabolic, memory deficits after chronic brain ischemia. Neurol Res 1992;14(suppl):177–180.
  27. de la Torre JC, Fortin T, Park G, Pappas B, Saunders J, Richard M: Brain blood-flow restoration ‘rescues’ chronically damaged rat CA1 neurons. Brain Res 1993;623:6–15.
  28. de la Torre JC, Pappas BA, Fortin T, Keyes M, Davidson C: Progressive neurodegeneration in rat brain after chronic 3-VO or 2-VO; in Fiskum G (ed): Neurodegenerative Diseases. New York, Plenum Press, pp 77–84, 1996.
  29. Matsuda H: The role of neuroimaging in mild cognitive impairment. Neuropathology 2007;27:570–577.
  30. Rodriguez G, Vitali P, Calvini P, Bordoni C, Girtler N, Taddei G, Mariani G, Nobili F: Hippocampal perfusion in mild cognitive impairment. Psychiatry Res 2000;100:65–74.
  31. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, Pirraglia E, De Santi S, Reisberg B, Wisniewski T, de Leon MJ: FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2009;36:811–822.
  32. de la Torre JC, Fortin T, Saunders J: Correlates between NMR spectroscopy, diffusion weighted imaging and CA1 morphometry following chronic brain ischemia. J Neurosci Res 1995;41:238–245.
  33. Cada A, de la Torre JC, Gonzalez-Lima F: Chronic cerebrovascular ischemia in aged rats: effects of brain metabolic capacity and behavior. Neurobiol Aging 2000;21:225–234.
  34. Abdollahian NP, Cada A, Gonzalez-Lima F, de la Torre JC: Cytochrome oxidase: a predictive marker of neurodegeneration; in Gonzalez-Lima F (ed): Cytochrome Oxidase in Neuronal Metabolism and Alzheimer’s Disease. New York, Plenum Press, 1998, pp 233–261.
  35. de la Torre JC, Aliev G: Inhibition of vascular nitric oxide after rat chronic brain hypoperfusion: spatial memory and immunocytochemical changes. J Cerebral Blood Flow Metab 2005;25:663–672.
  36. Obrenovich ME, Smith MA, Siedlak SL, Chen SG, de la Torre JC, Perry G: Overexpression of GRK2 in Alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotox Res 2000;10:43–56.

    External Resources

  37. De Jong GI, Farkas E, Stienstra CM, Plass JR, Keijser JN, de la Torre JC, Luiten PG: Cerebral hypoperfusion yields capillary damage in the hippocampal CA1 area that correlates with spatial memory impairment. Neuroscience 1999;91:203–210.
  38. Sopala M, Danysz W: Chronic cerebral hypoperfusion in the rat enhances age-related deficits in spatial memory. J Neural Transm 2001;108:1445–1456.
  39. Farkas E, Luiten PG: Cerebral microvascular pathology in aging and Alzheimer’s disease. Prog Neurobiol 2001;64:575–611.
  40. Ni JW, Matsumoto K, Li HB, Murakami Y, Watanabe H: Neuronal damage and decrease of central acetylcholine level following permanent occlusion of bilateral common carotid arteries in rat. Brain Res 1995;673:290–296.
  41. Otori T, Katsumata T, Muramatsu H, Kashiwagi F, Katayama Y, Terashi A: Long-term measurements of cerebral blood flow and metabolism in a rat chronic hypoperfusion model. Clin Exp Pharmacol Physiol 2003;30:266–272.
  42. Tsuchiya M, Sako K, Yura S, Yonemasu Y: Local cerebral glucose utilisation following acute and chronic bilateral carotid artery ligation in Wistar rats: relation to changes in local cerebral blood flow. Exp Brain Res 1993;95:1–7.
  43. Sekhon LH, Spence I, Morgan MK, Weber NC: Chronic cerebral hypoperfusion inhibits calcium-induced long-term potentiation in rats. Stroke 1997;28:1043–1048.
  44. Liu HX, Zhang JJ, Zheng P, Zhang Y: Altered expression of MAP-2, GAP-43, and synaptophysin in the hippocampus of rats with chronic cerebral hypoperfusion correlates with cognitive impairment. Brain Res Mol Brain Res 2005;139:169–177.
  45. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR: ‘Preclinical’ AD revisited: neuropathology of cognitively normal older adults. Neurology 2000;55:370–376.
  46. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, Smith GE, Dickson DW, Johnson KA, Petersen LE, McDonald WC, Braak H, Petersen RC: Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 2003;62:1087–1095.
  47. Giannakopoulos P, Herrmann FR, Bussire T, et al: Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology 2003;60:1495–1500.
  48. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR: Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999;58:376–388.
  49. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE: Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509–1517.
  50. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA: Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216–223.
  51. de la Torre JC: Critically attained threshold of cerebral hypoperfusion (CATCH): can it cause Alzheimer’s disease? Ann NY Acad Sci 2000;903:424–436.
  52. Solfrizzi V, Capurso C, D’Introno A, Colacicco AM, Santamato A, Ranieri M, Fiore P, Capurso A, Panza F: Lifestyle-related factors in predementia and dementia syndromes. Expert Rev Neurother 2008;8:133–158.
  53. Singh-Manoux A, Sabia S, Lajnef M, Ferrie JE, Nabi H, Britton AR, Marmot MG, Shipley MJ: History of coronary heart disease and cognitive performance in midlife: the Whitehall II study. Eur Heart J 2008, Epub ahead of print.
  54. Zhiyou C, Yong Y, Shanquan S, Jun Z, Liangguo H, Ling Y, Jieying L: Upregulation of BACE1 and beta-amyloid protein mediated by chronic cerebral hypoperfusion contributes to cognitive impairment and pathogenesis of Alzheimer’s disease. Neurochem Res 2009;34:1226–1235.
  55. Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337–1342.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50